Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
調査の概要
詳細な説明
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) for the combination of bortezomib and romidepsin administered weekly x 3 every (q) 4wk in patients with CLL/SLL, indolent B-cell lymphoma, PTCL or cutaneous T-cell lymphoma (CTCL).
Secondary
- Determine safety and tolerance and describe the toxicities of the combination.
- Demonstrate adequate methods for the assessment of pharmacodynamic responses of CLL cells to the combination with respect to effects on NF-kappa B (nuclear RelA and processing of p52 as a marker of p100 processing), expression of the NF-kappa B-dependent proteins XIAP and Bcl-xL, and Bim, and document pharmacodynamic responses observed in the course of this study * Document the pharmacodynamic responses associated with this regimen in these patients.
- Document the anticancer activity of this regimen in these patients.
OUTLINE: Patients receive bortezomib IV over 3-5 seconds and romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood samples from patients with chronic lymphocytic leukemia are collected at baseline and after day 1 of course 1 of study treatment for pharmacodynamic and correlative laboratory studies.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland Greenebaum Cancer Center
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- University of North Carolina
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt-Ingram Cancer Center, Vanderbilt University
-
-
Virginia
-
Richmond、Virginia、アメリカ、23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
* Diagnosis of 1 of the following:
- CLL or SLL, relapsed or refractory
Indolent B-cell lymphoma, relapsed or refractory:
- Follicle center lymphoma, follicular or diffuse
- Marginal zone B-cell lymphoma (splenic, nodal, extranodal [this includes mucosa associated lymphoid tissue (MALT)])
- Lymphoplasmacytic lymphoma
PTCL, relapsed or refractory:
- Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-positive
- Anaplastic large cell lymphoma, ALK-negative
- Angioimmunoblastic T-cell lymphoma
- Enteropathy-associated T-cell lymphoma
- Extranodal natural killer (NK)/T-cell lymphoma, nasal type
- Hepatosplenic T-cell lymphoma
- PTCL, not otherwise specified (NOS)
- Subcutaneous panniculitis-like T-cell lymphoma
CTCL:
* CTCL with subtypes of mycosis fungoides Stage IB or higher, Sézary syndrome, or primary cutaneous anaplastic large cell lymphoma who have failed a previous systemic treatment, as per the following:
- Stage IA plaque, IB, or IIA: At least 4 prior conventional and/or experimental regimens (topical or systemic, including psoralen-ultraviolet light [PUVA] and systemic corticosteroids)
- Stage IIB, III, or IV: At least 1 prior systemic regimen (systemic corticosteroids alone or PUVA alone do not count as systemic regimens for this purpose) NOTE: Repeated use of the same regimen is considered 1 regimen
Prior allogeneic stem cell transplant is allowed provided that all of the following conditions are met:
- >= 6 months have elapsed since allogeneic transplant
- No Graft vs. Host Disease (GVHD) is present
- Not currently on immunosuppressive therapy
- No prior or concurrent CNS malignancy
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- ANC > 1,500/mm^3
- Platelet count > 75,000/mm^3
- Hemoglobin > 7.5 g/dL (transfusion allowed)
- Serum creatinine ≤ 1.2 mg/dL or actual or calculated creatinine clearance > 60 mL/min
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ ULN
- Serum potassium ≥ 3.5 mEq/L (supplementation allowed)
- Serum magnesium ≥ 1.7 mEq/L (supplementation allowed)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective non-hormonal contraception
- Willing and able to comply with protocol requirements
- No prior severe allergic reactions to bortezomib, boron, mannitol, or romidepsin
- No progressing toxicity secondary to bortezomib
- No grade 1 peripheral neuropathy with pain or ≥ grade 2 peripheral neuropathy by NCI-CTCAE criteria (v4.0) within the past 14 days
No condition related to ischemic heart disease, heart failure, or the risk of torsades de pointes or sudden cardiac death, including any of the following:
- History of sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes, or resuscitated cardiac arrest unless currently addressed with an implantable cardiac defibrillator
- Baseline heart rate > 140 beats per minute
- Known congenital long QT syndrome
- QTc interval > 480 milliseconds
- Type II second-degree atrio-ventricular (AV) block, third-degree AV block, or ventricular rate < 50 beats per minute
Myocardial infarction within the past 6 months
- Patients who have had a myocardial infarction 6-12 months ago are eligible provided they are asymptomatic and have a negative cardiac risk assessment (i.e., treadmill stress test, nuclear medicine stress test, or stress echocardiogram)
Angina upon ordinary physical activity
- Angina only with strenuous, rapid, or prolonged exertion allowed
ECG with evidence of cardiac ischemia, as defined by the following:
- ST depression of ≥ 2 mm, measured from isoelectric line to ST segment
- T-wave inversion ≥ 4 mm, measured from isoelectric line to peak of T-wave
- NYHA class II-IV congestive heart failure
- Known left ventricular ejection fraction < 40% by MUGA scan or < 50% by echocardiogram or MRI
- Known hypertrophic cardiomegaly or restrictive cardiomyopathy
- No uncontrolled hypertension, defined as persistent blood pressure ≥ 160/95 mm Hg despite medical management
- No clinically significant active infection, including known HIV infection or hepatitis B or C
- No other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, in situ malignancy, or curatively treated low-risk prostate cancer
- No concurrent medical condition that, in the investigator's opinion, would compromise study treatment or assessment of toxicity
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 3 weeks since prior chemotherapy, radiation therapy or investigational agents. If steroids for cancer control have been used, patients must be off theses agents for at least 1 week before starting treatment. (Maintenance therapy for non-malignant disease with prednisone or steroid equivalent dose less than 10 mg/day is permitted)
- Prior allogeneic stem cell transplantation allowed provided all of the following conditions are met:
- Greater than or equal to 6 months have elapsed since allogeneic transplant
- No Graft vs. Host Disease (GVHD) is present
- More than 4 weeks since prior bortezomib
- No concurrent oral hormonal contraceptives
- No concurrent potent or moderate CYP3A4 inhibitors
- No concurrent anti-arrhythmic agents
No concurrent treatment with any drugs that are generally accepted to having a risk of causing torsades de pointes (class 1 drugs)
- Class 2 or 3 drugs allowed at the discretion of the investigator
- No other concurrent systemic therapy for the malignancy
- Concurrent warfarin (coumadin) allowed
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:bortezomib + romidepsin
Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks.
In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
|
Starting dose: 1.3 mg/sq m
他の名前:
Starting dose: 8 mg/sq m
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum tolerated dose
時間枠:2 years
|
Dose at which no more than 1 dose-limiting toxicity is observed in as many as 6 patients
|
2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacodynamic responses
時間枠:2 years
|
To explore candidate pharmacodynamic markers for use in subsequent phase II trials.
|
2 years
|
協力者と研究者
捜査官
- 主任研究者:Thomas C. Shea, MD、UNC Lineberger Comprehensive Cancer Center
- スタディチェア:Steven Grant, MD、Virginia Commonwealth University
- 主任研究者:Sho Ma, MD, PhD、Northwestern University & Robert H Lurie Comprehensive Cancer Center
- 主任研究者:Amy Kimball, MD, PhD、University of Maryland Greenebaum Cancer Center
- 主任研究者:Nishitha Reddy, MBBS、Vanderbilt-Ingram Cancer Center, Vanderbilt University
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- MCC-12215 (その他の識別子:VCU Massey Cancer Center)
- P30CA016059 (米国 NIH グラント/契約)
- R21CA137823 (米国 NIH グラント/契約)
- CDR0000652509 (レジストリ識別子:PDQ)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。